

IN THE CLAIMS:

Please enter the following new claims:

19. ✓ A method of immunotherapy comprising administering CD38, or a portion of CD38 or an analogue of CD38, wherein the CD38, or portion of CD38 or analogue of CD38 inhibits the binding of CD38 to non-follicular dendritic cell (DC) or a follicular dendritic cell (FDC) and retains the ability of CD38 to stimulate a DC or FDC.
20. The method of claim 19, wherein the portion is an extracellular domain portion.
21. The method of claim 19, wherein the analogue is a fusion protein comprising an extracellular domain portion of CD38 and a non-CD38 sequence.
22. ✓ A method of causing maturation of DCs comprising contacting DCs *ex vivo* with an antigen and a CD38, a portion of CD38 or an analogue of CD38.
23. The method of claim 22, wherein the DCs are simultaneously contacted with the antigen and CD38, a portion of CD38 or an analogue of CD38 under conditions such that the DCs correspond to DCs subject to T cell signaling.
24. ✓ A vaccine comprising an antigenic component and an adjuvant component, wherein said adjuvant component comprises CD38, a portion of CD38 or an analogue of CD 38, wherein the CD38, or portion of CD38 or analogue of CD38 inhibits the binding of CD38 to non-follicular dendritic cell (DC) or a follicular dendritic cell (FDC) and retains the ability of CD38 to stimulate a DC or FDC.
25. The vaccine of claim 24, wherein the antigenic component comprises a CD8 T cell epitope.
26. An *ex vivo* mature DC produced in claim 22.
27. A method of preventing a disease comprising administering the DC of claim 26.
28. A method of treating a disease comprising administering the DC of claim 26.
29. A method of stimulating a T cell response *in vivo* comprising administering the DC of claim 26.

30. A vaccine comprising the DC of claim 26.

31. A method of stimulating T cells specific to an epitope *in vitro* comprising contacting the T cells with the DC of claim 26 under conditions in which the DC presents the epitope to the T cell.

32. ✓ A ligand of CD38 comprising a native ligand present on a FDC or DC which binds CD38 and is substantially free of FDC or DC cell membrane, excluding CD31, a protein which is at least 70% homologous to a native CD38 ligand, or a fragment thereof which retains the ability to bind CD38.

33. A polynucleotide sequence encoding the ligand of claim 32.

34. An antibody that binds immunologically to the ligand of claim 32.

35. The antibody of claim 34, wherein the antibody inhibits the binding of CD38 to the ligand.

36. ✓ A method of identifying an adjuvant comprising contacting a CD38 ligand present on FDCs or DCs with a candidate substance in the presence of a CD38 analogue and determining whether the substance competes with CD38 or the analogue for binding to the CD38 ligand or whether the substance is capable of maturing DCs.

37. The method of claim 36, wherein the ligand is a native ligand, a protein which is at least 70% homologous to a native CD38 ligand, or a fragment thereof which retains the ability to bind CD38.

38. A method of immunotherapy comprising administering an analogue of CD38 which inhibits the binding of CD38 to a DC or a FDC and retains the ability of CD38 to stimulate a DC or FDC, wherein the analogue is an adjuvant which is identified in claim 36.

39. A method of causing maturation of DCs comprising contacting DCs *ex vivo* with an analogue of CD38, wherein the analogue is an adjuvant identified in claim 36.

40. A vaccine comprising an antigenic component and an adjuvant, wherein the adjuvant component comprises a CD38 analogue which inhibits the binding of CD38 to a DC or a FDC and retains the ability of CD38 to stimulate a DC or FDC, wherein the analogue is an adjuvant identified in claim 36.

41. ✓ An inhibitor of CD38 ligand comprising a compound that inhibits activation of CD38 ligand by CD38.

42. A method of immunosuppression comprising administering an inhibitor of claim 41.

Please cancel, without prejudice and without acquiescence, claims 1-18.

FOIb0021-000000000000000000